检测吡咯里西啶生物碱辅助诊断肝窦阻塞综合征

肝脏 ›› 2022, Vol. 27 ›› Issue (10): 1112-1115.

检测吡咯里西啶生物碱辅助诊断肝窦阻塞综合征

邵幼林, 熊爱珍, 张锁才, 吴剑明, 马春明, 郭风彩, 柳龙根

213001 江苏常州市第三人民医院肝病科(邵幼林,张锁才,吴剑明,马春明,郭风彩,柳龙根);上海中医药大学中药研究所中药标准化教育部重点实验室暨国家中医药管理局中药新资源与质量评价重点实验室(熊爱珍)

收稿日期:2022-05-27 出版日期:2022-10-31 发布日期:2022-11-22
通讯作者: 柳龙根,Email:ssewllg@163.com;熊爱珍,Email:a.z.xiong@hotmail.com
基金资助:
常州市应用基础研究计划项目(CJ20190080);上海市人才发展资金(2020099)

Hepatotoxic pyrrolizidine alkaloid detection accurately diagnosed HPA-HSOS

SHAO You-lin¹, XIONG Ai-zhen², ZHANG Suo-cai¹, WU Jian-ming¹, MA Chun-ming¹, GUO Feng-cai¹, LIU Long-gen¹

1. Department of Hepatology, Changzhou Third People's Hospital, Changzhou 213001, China;
2. The Ministry of Education Key Laboratory for Standardization of Chinese Medicines and the State Administration of Traditional Chinese Medicine Key Laboratory for New Resources and Quality Evaluation of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Shanghai 201203, China

Received:2022-05-27 Online:2022-10-31 Published:2022-11-22
Contact: LIU Long-gen, Email:ssewllg@163.com; XIONG Ai-zhen, Email:a.z.xiong@hotmail.com

摘要/Abstract

摘要： 目的探讨检测摄入物中吡咯里西啶生物碱(HPA)成分辅助诊断肝窦阻塞综合征(HPA-HSOS)的可行性。方法收集1例服用菊三七叶和 4例服用三七粉或三七酒患者的临床资料。Acquity Ultra Performance LCTM-Micromass ZQ 2000液质联用仪检测患者服用物中千里光菲灵碱、千里光碱、菊三七碱甲及其N-氧化物等6种主要肝毒性HPA的含量。结果 4例患者诊断HPA-HSOS,1例患者排除HPA-HSOS。菊三七根、茎、叶中均含有HPA,HPA含量为根＞叶＞茎。结论通过检测患者服用物中肝毒性HPA可诊断HPA-HSOS。

关键词: 菊三七, 肝窦阻塞综合征, 吡咯里西啶生物碱

Abstract: Objective To investigate the feasibility of detecting hepatotoxic pyrrolizidine alkaloids (HPA) in patients’ ingestion in the diagnosis of HPA-hepatic sinusoidal obstruction syndrome (HSOS). Methods Clinical datas were collected from 1 patient taking Gynura Segetum Lour and 4 patients taking “Sanqi powder” or “Sanqi wine”. Acquity Ultra Performance LCTM-Micromass ZQ 2000(UPLC-MS) was used to determine the levels of six major hepatotoxic pyrrolizidine alkaloids, including seneciphylline, seneciphylline N-oxide, senecionine, senecionine N-oxide, seneciphyllinine and seneciphyllinine N-oxide. Results ① 4 patients were diagnosed with HPA-HSOS, and 1 patient was excluded from HPA-HSOS. ② HPA was found in roots, stems and leaves of Gynura Segetum, and the content of HPA was root > leaf > stem. Conclusion HPA-HSOS can be accurately diagnosed by detecting HPA in patients’ ingestion.

Key words: Gynura segetum, Hepatic sinusoidal obstruction syndrome, Hepatotoxic pyrrolizidine alkaloid, Accurate diagnosis

邵幼林, 熊爱珍, 张锁才, 吴剑明, 马春明, 郭风彩, 柳龙根. 检测吡咯里西啶生物碱辅助诊断肝窦阻塞综合征[J]. 肝脏, 2022, 27(10): 1112-1115.

SHAO You-lin, XIONG Ai-zhen, ZHANG Suo-cai, WU Jian-ming, MA Chun-ming, GUO Feng-cai, LIU Long-gen. Hepatotoxic pyrrolizidine alkaloid detection accurately diagnosed HPA-HSOS[J]. Chinese Hepatolgy, 2022, 27(10): 1112-1115.

参考文献

[1] Ma C, Liu Y, Zhu L, et al. Determination and regulation of hepatotoxic pyrrolizidine alkaloids in food: a critical review of recent research. Food Chem Toxicol, 2018, 119: 50-60.
[2] 中华医学会消化病学分会肝胆疾病协作组. 吡咯生物碱相关肝窦阻塞综合征诊断和治疗专家共识意见(2017年,南京). 中华消化内镜杂志, 2017, 34: 533-542.
[3] Teschke R, Vongdala N, Quan NV, et al. Metabolic toxification of 1,2-unsaturated pyrrolizidine alkaloids causes human hepatic sinusoidal obstruction syndrome: the update. Int J Mol Sci, 2021, 22.
[4] Fang L, Xiong A, Yang X, et al. Mass-spectrometry-directed analysis and purification of pyrrolizidine alkaloid cis/trans isomers in Gynura japonica. J Sep Sci, 2014, 37: 2032-2038.
[5] Xiong A, Shao Y, Fang L, et al. Comparative analysis of toxic components in different medicinal parts of Gynura japonica and its toxicity assessment on mice. Phytomedicine, 2019, 54: 77-88.
[6] He Y, Zhu L, Ma J, et al. Metabolism-mediated cytotoxicity and genotoxicity of pyrrolizidine alkaloids. Arch Toxicol, 2021, 95: 1917-1942.
[7] Zhuge Y, Liu Y, Xie W, et al. Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome. J Gastroenterol Hepatol, 2019, 34: 634-642.
[8] 邵幼林, 张锁才, 吴剑明, 等. 菊三七相关肝窦阻塞综合征临床结局相关影响因素分析. 肝脏, 2021, 26(10): 1170-1175
[9] Kan X, Ye J, Rong X, et al. Diagnostic performance of contrast-enhanced CT in pyrrolizidine alkaloids-induced hepatic sinusoidal obstructive syndrome. Sci Rep, 2016, 6: 37998.
[10] Gao H, Ruan JQ, Chen J, et al. Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome. Drug Des Devel Ther, 2015, 9: 4861-4868.
[11] Xia Q, Zhao Y, Lin G, et al. Pyrrolizidine Alkaloid-Protein adducts: potential non-invasive biomarkers of pyrrolizidine alkaloid-induced liver toxicity and exposure. Chem Res Toxicol, 2016, 29: 1282-1292.
[12] Yang M, Ruan J, Gao H, et al. First evidence of pyrrolizidine alkaloid N-oxide-induced hepatic sinusoidal obstruction syndrome in humans. Arch Toxicol, 2017, 91: 3913-3925.
[13] He Y, Zhang W, Ma J, et al. Blood pyrrole-DNA adducts define the early tumorigenic risk in patients with pyrrolizidine alkaloid-induced liver injury. Environ Sci Technol Lett, 2021, 8: 551-557.